Company Encyclopedia
View More
name
Fh Therapeutics
FNCH.US
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn’s disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc.
1.875 T
FNCH.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
E
BiotechnologyIndustry
Industry Ranking379/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-67.28%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY89.63%A
    • Total Assets YoY-31.83%E
    • Net Assets YoY-49.02%E
  • Cash ScoreE
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreD
    • Gearing Ratio68.80%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Global Live Biotherapeutics Market set for rapid growth, reaching US$ 422.9 Mn by 2034 with 14% CAGR. Rising demand for microbiome therapies driving expansion. Key drivers include chronic disease prevalence, microbiome research advances, regulatory environment, and investments from industry players. Leading companies include Ferring Pharmaceuticals, Seres Therapeutics, 4D Pharma, Finch Therapeutics, and Vedanta Biosciences.

    The Global Live Biotherapeutics Market is projected to grow from US$105.5 million in 2023 to US$422.9 million by 2034, with a CAGR of 14%. This growth is driven by increasing demand for microbiome therapies, particularly for chronic diseases. Key factors include the prevalence of chronic illnesses, advancements in microbiome research, a supportive regulatory environment, and investments from industry players. Major companies in this sector include Ferring Pharmaceuticals, Seres Therapeutics, 4D Pharma, Finch Therapeutics, and Vedanta Biosciences.

    Unusual Whales·
    US
    FNCH
    -1.09%
    US
    MCRB
    -17.87%
    Unusual Whales·
    US
    FNCH
    -1.09%
    US
    MCRB
    -17.87%